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Background: Uncontrolled studies suggest that patients with chronic venous ulceration (CVU) have an increased
prevalence of thrombophilia, similar to that observed in patients with deep vein thrombosis. This study compared the
nature and prevalence of thrombophilia in patients with varicose veins (VV, CEAP clinical [C] grade C2 to C3) and
patients with CVU (C5 to C6) with an age- and sex-matched population without clinical or duplex ultrasound evidence
of venous disease.
Methods: Twenty-seven patients with VV, 27 patients with CVU, and 54 age- and sex-matched case controls with no
clinical or duplex evidence of lower limb venous disease, underwent testing for factor V Leiden and prothrombin 20210A
mutations, antithrombin deficiencies, and levels of antiphospholipid antibodies, homocysteine, protein C and S, and
factor VIII, IX, and XI.
Results: The overall prevalences of single and multiple thrombophilias were significantly higher in cases than in controls.
Specifically, in VV patients, the prevalences of no, single, and multiple thrombophilias were 33%, 52%, and 15%,
respectively, compared with 63%, 26%, and 11% in VV controls. In CVU patients, the prevalences of no, single, and
multiple thrombophilias was 26%, 30%, and 44%, respectively, compared with 66%, 22%, and 11% in CVU controls.
Compared with controls, only factor XI levels were significantly higher in VV patients, and homocysteine and factor VIII,
IX, and XI levels were all significantly higher in CVU patients.
Conclusion: Patients with VV, and particularly CVU, have significantly higher prevalences of single and multiple
thrombophilias than age- and sex-matched controls without clinical or duplex evidence of lower limb venous disease.
These data support the hypothesis that thrombophilia predisposes to the development of superficial and deep lower limb
venous reflux, and so VV and CVU, through the increased occurrence of clinical and subclinical thrombosis. ( J Vasc Surg
2009;49:1235-41.)Thrombophilia may be defined as an abnormality of the
coagulation or fibrinolytic systems that results in a hyper-
coagulable state. Thrombophilia may be inherited or ac-
quired, and the hypercoagulable state may arise either from
an excess (or hyperfunction) of a procoagulant or a defi-
ciency (or hypofunction) of an anticoagulant moiety.1 The
number of recognized thrombophilias continues to in-
crease and now includes elevated levels of coagulation
factors (F) VIII, IX, and XI, and hyperhomocysteinemia
(HHcy), as well as classic thrombophilia, such as protein C
deficiency.
All of these thrombophilias can predispose to lower
limb deep venous thrombosis (DVT). Because such DVT is
a well recognized risk factor for chronic venous insuffi-
ciency (CVI) and ulceration (CVU), often termed the
post-thrombotic syndrome, it is perhaps not surprising that
a number of uncontrolled studies have suggested that the
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and CVU is similar to that observed in patients after
DVT.1-6 To our knowledge however, only one study,
which was from our group, has looked at the prevalence of
elevated factor levels and HHcy in addition to the classic
thrombophilias.3 Furthermore, no study to date has com-
pared CVU patients and controls without venous disease.
One recent study looked at coagulation state (mea-
sured by protein C and S, fibrinogen, and Hcy) in patients
with varicose veins (VV), signifying uncomplicated lower
limb venous disease, compared with a control group with
no symptoms or signs of venous disease. No statistically
significant differences were found between the cases and
controls.7 The prevalence of raised procoagulant factors has
not been studied in patients with VV.
The aim of the present study, therefore, was to compare
for the first time the prevalence of thrombophilia in patients
with VV (CEAP clinical [C] grade 2 to 3),8 CVU (CEAP
C5 to C6), and an age- and sex-matched control population
without clinical or duplex ultrasound evidence of lower
limb venous disease.
METHODS
Ethical committee approval was obtained and all par-
ticipants provided fully informed written consent. Consec-
utive patients (cases) referred with either uncomplicated
VV (CEAP C2 to C3) or CVU (CEAP C5 to C6), and who
did not have a condition known to be associated with an
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to take part in the study. Controls were patients attending
nonvascular hospital-based clinics who similarly did not
have any of the conditions listed in Table I, had no evidence
of lower limb venous disease on clinical and duplex ultra-
sound (DU) examination (SonoSite Ltd, Hitchin, Herts,
UK), and were matched to cases by age (to 1 year) and
gender on a one-to-one basis.
All prospective cases and controls underwent DU ex-
amination of both lower limbs. Participants were examined
standing with their weight on the contralateral limb and the
leg to be examined slightly bent with the heel on the floor
to relax the calf muscle while maintaining stability. A
Sonosite 180 (Sonosite Ltd, Hitchin, Herts, United King-
dom) with a 5-MHz transducer was used. The following
venous segments were insonated: proximal and distal su-
perficial femoral vein, above and below knee popliteal vein,
saphenofemoral and saphenopopliteal junctions, the whole
length of the great saphenous vein, and the short saphenous
vein. All veins were assessed for patency and compressibil-
ity. Reflux was induced with a manual calf squeeze and was
defined as reverse flow 0.5 seconds.
Clinical examination of both lower limbs was per-
formed on all cases and controls to determine the CEAP
clinical [C] grade. Only those with CEAP C0 limbs were
included as controls. In the absence of symptoms and signs
suggestive of peripheral arterial disease, patients with pal-
pable pedal pulses or an ankle-brachial pressure index0.8
were considered suitable for inclusion in the study.
A nonfasting sample of blood was drawn from an
antecubital fossa vein of all participants and immediately
centrifuged at 2000g for 15 minutes at room temperature.
Hcy samples were centrifuged at 4°C to prevent cells con-
tinuing to produce Hcy in the tube.3 Serum and plasma
Table I. Exclusion criteria
All patients—cases and controls
Blood disorders
Previous venous thromboembolism
Previous superficial thrombophlebitis
Previous/current anticoagulant use
History of malignancy
Symptomatic arterial disease  ankle-brachial pressure index
0.8 if pedal pulses impalpable
Symptomatic ischemic heart disease (eg, angina, previous
cardiac surgery or angioplasty)
Connective tissue disorders, including rheumatoid arthritis
Any other known acute or chronic inflammatory process 3
months
Inflammatory bowel disease
Surgery 3 months
Orthopaedic surgery/fracture 6 months
Pregnancy—current or 6 months
Hypothyroidism or hyperthyroidism
Known hepatic or renal insufficiency
Control group only
Previous treatment for varicose veins
History of leg ulceration
Clinical/duplex ultrasound evidence of venous diseasewere stored at –80°C until assayed. Extracted cells wereused to screen for PT20210A and factor V Leiden poly-
morphisms using standard polymerase chain reaction
(PCR) techniques.9,10 The total plasma Hcy concentration
was determined using high-pressure liquid chromatogra-
phy (DS30; Drew, Cumbria, UK) as previously described.3
HHcy was defined as a total plasma Hcy level 90th
percentile observed in the controls (16.6 mol/L).
All other assays were performed on a fully automated
coagulation analyzer using standard reagents (MDA II,
Biomerieux, Basingstoke, Hampshire, UK). Factors VIII,
IX, and XI weremeasured by a one-step clotting assay using
clotting factor-deficient plasma. Values were reported as
percentage (%) activity, where 100% equals 100 IU/dL.
Elevated factor activities were defined as those 90th per-
centile observed in the controls. A clotting-assay was used
to measure protein S, and chromogenic assays were used to
measure protein C and antithrombin. Local reference
ranges were used, the lower limits of which were 70%, 60%,
and 70% activity for protein C, protein S, and antithrombin,
respectively. The dilute Russell viper venom test was used
to detect lupus anticoagulant (Life Therapeutics, Sydney,
Australia). Anticardiolipin antibodies were detected using
an enzyme-linked immunosorbent assay (ELISA; Grifols
UK Ltd, Cambridge, UK). All positive results (using local
reference ranges) for any antiphospholipid antibody were
repeated at least 6 weeks later. C-reactive protein (CRP)
was determined in the control group by immunologic
methods (Quantex CRP Plus, Biokit, Barcelona, Spain).
Erythrocyte sedimentation rate (ESR) was measured using
the Starrsed Compact analyser (Mechatronics BV, Nether-
lands) and a Westergren-based method.
All assays were performed under the direct supervision
of one of the authors (C. F.) as a single batch in an
accredited laboratory by technicians blinded to the origin
of the sample. A sample size calculation indicated that up to
27 patients would be required in each of the four groups to
detect a difference of at least 30% in the activities of factors
VIII, IX, and XI, and of 4 mol/L in plasma Hcy levels,
with two-tailed 5% significance level and a power of 80%
(specific sample sizes required were 27, 23, 19, and 17 for
factors VIII, IX, and XI and Hcy, respectively).
Statistical analysis was divided into three parts. First,
the Kolmogorov-Smirnov test was used to determine nor-
mality of the data and thus the suitability of parametric
methods. Second, correlation and linear regression was
used to examine the association between the procoagulant
and anticoagulant factors, ESR, CRP, and age. Third, mean
values from cases and controls were compared using a
paired t-test. Differences in proportions were calculated
using the McNemar test, and odds ratios (ORs) with 95%
confidence intervals (CIs) were calculated. Data analysis
was done with SPSS 11.0 software (SPSS Inc, Chicago, IL).
RESULTS
There were 27 VV (CEAP C2 to C3) patients (12 men)
aged a mean of 54.3 years (range, 30-77 years), 27 CVU
(CEAP C5 to C6) patients (11 men) aged a mean of 72.0
years (range, 35-88 years), and 54 age- and sex-matched
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symptomatic (CS) and had primary disease (EP); all had
saphenous incompetence (AS), and nine also had deep
(non-post-thrombotic) venous incompetence (ASD); and
patients had reflux (PR), not obstruction. All venous seg-
ments were patent and compressible on DU imaging.
Overall, the prevalences of single and multiple throm-
bophilias were significantly higher in cases than in controls.
Specifically, in VV cases, the prevalences of no, single, and
multiple thrombophilias were 33%, 52%, and 15%, respec-
tively, compared with 63%, 26%, and 11% in VV controls.
The prevalences of no, single, and multiple thrombo-
philias were 26%, 30%, and 44%, respectively, in CVU cases
compared with 66%, 22%, and 11% in CVU controls (Fig 1).
By contrast, 75% of CVU cases and 66% of VV cases had
at least one thrombophilia, and 44% of CVU cases had
multiple thrombophilias. The prevalence and levels, where
appropriate, of individual thrombophilia are summarized in
Table II and Figs 2-5.
Four participants had heterozygous factor V Leiden (2
VV controls, 2 CVU cases); none had the PT20210A
mutation; 1 had lupus anticoagulant (VV case), 2 had
anticardiolipin antibodies (VV case), 1 had protein C defi-
ciency (VV case), 5 had protein S deficiency (2 CVU cases,
2 VV cases, and 1 VV control), and 5 had antithrombin
deficiency (3 CVU cases, 1 VV case, and 1 CVU control).
No significant differences were found between cases and
controls for factor V Leiden or PT20210A mutations,
lupus anticoagulant, and anticardiolipin antibodies, or de-
ficiencies of protein C, protein S, or antithrombin.
HHcy (defined as 16.6 mol/L) was significantly
more common in CVU cases than in CVU controls (40.7%
vs 7.4%; OR, 5.50; 95% CI, 1.20-51.07), but was similar in
VV cases and controls (16.0% vs 12.0%; OR, 2.00; 95% CI,
0.43-12.36). Hcy levels were significantly higher in all cases
Fig 1. The prevalence of thrombophilia (TP) in patients
VV, varicose veins.compared with all controls combined (mean difference[MD], 3.74; 95% CI, 2.09-5.38; P  .0005) and signifi-
cantly higher in CVU cases than in CVU controls (MD,
5.23; 95% CI, 2.99-7.47; P .0005). Although mean Hcy
levels were also higher in VV cases than in VV controls
(MD, 2.12; 95% CI –0.286 to 4.53; P .082), this did not
and without venous disease.CVU, chronic venous ulcer;
Table II. Individual thrombophilia data
Variable
CVU, No. (%) VV, No. (%)
Cases Controls Cases Controls
n  27a N  27a n  27b n  27b
Homocysteine
16.6 mol/Lc 11 (40.7) 2 (7.4) 4 (16.0) 3 (12.0)
Factor VIII
132% activityc 8 (29.6) 3 (11.1) 3 (11.1) 2 (7.4)
108% activityd 10 (66.7) 1 (6.7) 8 (40.0) 3 (15.0)
Factor IX
155% activityb 4 (14.8) 4 (14.8) 2 (7.4) 2 (7.4)
Factor XI
130% activityb 9 (33.3) 2 (7.4) 6 (22.2) 3 (11.1)
Factor V Leiden
heterozygote 2 (7.4) 0 0 2 (7.4)
PT20210A mutation 0 0 0 0
Lupus anticoagulant 0 0 1 (3.7) 0
ACLA, No. (%) 0 0 2 (7.4) 0
Protein C 70%
activity 0 0 1 (3.7) 0
Protein S 60%
activity 2 (7.4) 0 2 (7.4) 1 (3.7)
AT 70% activity 3 (11.1) 1 (3.7) 1 (3.7) 0
ACLA,Anticardiolipin antibodies;AT, antithrombin;CVU, chronic venous
ulcer; VV, varicose veins.
an  15 for CVU groups for factor VIII 108%.
bn  25 for VV groups for homocysteine and 20 for factor VIII 108%.
cValue used is 90th percentile for control group (n  54).
dValue used is 90th percentile for control group excluding thosewithC-reactive
proteinCRP5mg/L erythrocyte sedimentation rate15mm/h (n35).withreach significance (Fig 2).
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significant positive associationwithCRP (r .324,P .019)
and ESR (r  .475, P  .0005). We therefore decided to
analyze the data before and after excluding cases and controls
with elevated CRP (5 mg/L) or ESR (15 mm/h), or
both, in an attempt to remove any confounding effects of
on-going inflammatory processes. With the upper limit of
normal activity defined as the 90th percentile of levels in all
controls, CVU cases demonstrated an almost threefold higher
prevalence of elevated factor VIII activity (29.6%) than CVU
Fig 2. Box and whisker plots indicating total homocysteine levels
for cases vs controls. The horizontal line inside each box indicates the
median; the box itself represents the interquartile range (IQR); the
dots represent outliers which are observations lying more than 1.5
times the IQR from the first and third quartile; the whiskers indicate
the largest and smallest values that are not outliers. P values shown
from paired t test. CVU, chronic venous ulcer; VV, varicose veins.
Fig 3. Box and whisker plots indicating factor VIII activity in cases
vs controls. The horizontal line inside each box indicates the median;
the box itself represents the interquartile range (IQR); the dots
represent outliers which are observations lying more than 1.5 times
the IQR from the first and third quartile; the whiskers indicate the
largest and smallest values that are not outliers. P values shown
from paired t test. CVU, chronic venous ulcer; VV, varicose veins.controls (11.1%; OR, 2.00; 95% CI, 0.54-9.08). However,when the analysis was repeated after excluding cases and
controls with elevatedCRPor ESR levels, or both, CVUcases
had a 10-fold higher prevalence of elevated factor VIII levels
(66.7%) than CVU controls (6.7%; P .041, McNemar test;
OR not possible as denominator is 0).
In VV cases and controls, when all the participants were
included in the analysis, only a negligible difference was
found in the prevalence of high factor VIII activity between
CEAP C2 to C3 cases (11.1%) and controls (7.4%; OR,
Fig 4. Box and whisker plots indicating factor IX activity in cases vs
controls. The horizontal line inside each box indicates themedian; the
box itself represents the interquartile range (IQR); the dots represent
outliers which are observations lying more than 1.5 times the IQR
from the first and third quartile; the whiskers indicate the largest and
smallest values that are not outliers. P values shown from paired t
test. CVU, chronic venous ulcer; VV, varicose veins.
Fig 5. Box and whisker plots indicating factor XI activity in cases vs
controls. The horizontal line inside each box indicates themedian; the
box itself represents the interquartile range (IQR); the dots represent
outliers which are observations lying more than 1.5 times the IQR
from the first and third quartile; the whiskers indicate the largest and
smallest values that are not outliers. P values shown from paired t
test. CVU, chronic venous ulcer; VV, varicose veins.2.00; 95% CI, 0.29-22.11). As with CVU cases and con-
nous
, prot
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or both, were excluded from the analysis, VV cases exhib-
ited an almost threefold higher prevalence of raised factor
VIII levels (40.0%) than controls (15.0%; OR, 3.00; 95%
CI, 0.24-157.49). Factor VIII activity was significantly
higher in all cases combined compared with all controls
combined (MD, 23.26; 95% CI, 6.09-40.42; P  .009)
and significantly higher in CVU cases than CVU controls
(MD, 38.00; 95% CI, 8.57-67.43; P .015). Mean factor
VIII activity was also higher in VV cases than controls, but
this difference did not reach statistical significance (MD,
12.2; 95% CI, –9.17 to 33.57; P  .247; Fig 3).
The prevalence of elevated factor IX levels in the
present study was low (about 10%; Table II), and no
Table III. Prevalence of thrombophilia in patients with va
general population
Thrombophilia
Factor V Leiden Present in 5% of white populatio
2 CVU controls (7.4%) in this
reported a 7.7%-36% prevalen
PT20210A mutation Present in 2% of the white popu
prevalence in CVU patients, b
APLA Present in 2%-10% of the popula
patients with CVU,5,17,18 but
AT deficiency (70%
activity)
Present in 0.2% of the populatio
which is higher than the 5%
PC deficiency (70%
activity)
Present in 0.3% of the populatio
Previous studies have produce
activity in 25% of patients with
CVU cases vs controls.15 Yasi
compared with controls.7
PS deficiency (60% activity) Found in 0.2% of the population
studies have produced conflic
of patients with LDS and CVU
CVU cases.18 Yasim et al also
VV vs controls, but all values
HHcy Often defined as an Hcy level 
is present in 5% of the popula
3-fold increase in DVT risk.22
controls, similar to our previo
controls, similar to recent find
Elevated FVIII levels (90th
percentile)
Present in 10% of the population
DVT increases by 10% with ea
normal range28,29; recurrence
baseline levels; other factors (
infection, inflammation and m
and VV patients (to a lesser ex
Elevated FIX levels (90th
percentile)
Present by definition in 10% of t
risk of DVT, which is also line
high risk of DVT, indicating a
pressure, smoking, and blood
study may be because the 90t
for the general population. If
elevated FIX is observed in 55
were significantly higher in CV
patients and controls.
Elevated FXI levels (90th
percentile)
Present by definition in 10% of t
The present study clearly show
patients vs controls.
APLA, Antiphospholipid antibodies; AT, antithrombin; CVU, chronic ve
homocysteine; HHcy, hyperhomocystinemia; LDS, lipodermatosclerosis; PCdifferences were noted in the incidence of raised factorIX between the CVU cases and CVU controls or the VV
cases and the VV controls. Factor IX activity was signif-
icantly higher in all cases compared with all controls
(MD, 18.44; 95% CI, 4.46-32.43; P  .011) and in
CVU cases compared with CVU controls (MD, 24.78;
95% CI, 5.24-44.31; P  .015). However, there was no
difference in factor IX activity between VV cases and
controls (Fig 4).
Elevated factor XI was much more common in CVU
cases (33.3%) than CVU controls (7.4%;OR, 4.50; 95%CI,
0.93-42.80) and in VV cases (22.2%) than in VV controls
(11.1%; OR, 2.00; 95% CI, 0.54-9.08). Factor XI activity
was significantly higher in all cases compared with all con-
trols (MD, 21.4; 95% CI, 8.54-34.31; P  .002), in CVU
e veins and chronic venous ulcer compared with the
Comment
18%-20% post-DVT patients.1,11 Found in 2 CVU patients and
y; similar to previous reports from our group.2 Others have
FVL in CVU patients.4,5,12-14
and 6% of post-DVT patients. Previous studies report a 0%-4%
t found in this study.1,2,9,11,15,16
and 10%-20% of post-DVT patients.1,2 Reported in up to 59% of
report a prevalence similar to the present study (5.6%).2,16
1% of patients with DVT. Found here in 11% of CVU patients,
rted previously by our group and others.2,6
3% of patients with DVT. Found here in only 1 VV patient.
flicting results2,15,19,20: one group found a reduction in PC
S and CVU;20 but another found no difference in PC activity in
l found no difference in PC activity in patients with VV
5% of DVT patients. Not found in present study. Previous
esults:2,15,20 one study reported low levels of PS activity in 25%
ut another found a nonsignificant increase in PS activity in
d recently significantly higher levels of PS activity in patients with
within normal range.7
ol/L (95th percentile in the normal population); by definition,
1 An increase of 5 mol/L is believed associated with an 2- to
cy levels were significantly higher in our CVU patients vs
ort.3 In our study, Hcy levels did not increase in VV patients vs
of Yasim et al.7
20% to 25% of post-DVT patients.17,26,27 The risk of a first
% increase in activity, even when FVIII values are within the
rombosis is common.30,31 Hereditary factors appear to set the
y, smoking, hormones, exercise, acute phase reactants, eg,
ancy) can lead to a further rise. The present study shows CVU
had significantly increased FVIII levels vs controls.
pulation and associated with an almost 3-fold increase in the
,32-34 Patients with both high FVIII and FIX are at especially
itive effect. Causes of raised FIX include age, sex, obesity, blood
.35 The low prevalence of raised FIX (10%) in the present
centile in controls (155%) was higher than in published reports
0th percentile from the Leiden study is used (129%),36 then
f CVU patients and 22.2% of CVU controls. Mean FIX levels
atients than in controls. There was no difference between the VV
pulation and associated with a 2-fold increase in DVT risk.37
increased prevalence of elevated FXI in both CVU and VV
ulcer; DVT, deep vein thrombosis; F, factor; FVL, factor V Leiden; Hcy,
ein C; PS, protein S.ricos
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stud
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with VV controls (MD, 16.19; 95% CI, 2.13-30.25; P 
.026; Fig 5).
DISCUSSION
The principal finding of this study is that patients with
lower limb venous disease, whether that be uncomplicated
VV or CVU, have a much higher prevalence of thrombo-
philia than an age- and sex-matched population without
clinical or DU evidence of venous disease (Table III). The
prevalence of thrombophilia in VV patients, but especially
in CVU patients, approaches that observed in post-DVT
patients, and the prevalence of thrombophilia in the control
groups was similar to that observed in the general popula-
tion.1,2 CVU patients were also significantly more likely to
have multiple thrombophilias than controls.
What is the clinical significance of these novel findings?
Although the pathophysiology of CVU is incompletely
understood, it is generally accepted that at a macrovascular
level, the signs and symptoms of chronic venous insuffi-
ciency are the end result of sustained ambulatory venous
hypertension. This in turn results from venous reflux and
obstruction, which frequently develops secondary to DVT
as part of the post-thrombotic syndrome. These macrovas-
cular abnormalities lead to a complex series of molecular
and cellular events at the microvascular level within the
skin; for example, the development of a fibrin cuff, poly-
morphonuclear and mononuclear infiltration, release of
cytokines, expression of adhesion molecules, and local
thrombosis.1
Given the important role of macrovascular and micro-
vascular thrombosis in the development of CVI, and be-
cause patients with thrombophilia are prone to the devel-
opment of extensive and recurrent DVT at an early age, it is
perhaps not surprising that various groups have reported an
apparent excess of thrombophilia in patients with CVU.1
However, these earlier reports were of small numbers of
patients, addressed only a limited range of thrombophilias,
did not include patients with earlier stage venous disease,
and were uncontrolled. The present study is, therefore, to
our knowledge the first to compare the prevalence of a wide
range of currently known thrombophilias in patients with
CVU and uncomplicated VV with a series of age- and
sex-matched case controls shown not to have superficial or
deep lower limb venous disease on clinical examination
and, importantly, also DU imaging.
The present data support the hypothesis that thrombo-
philia predisposes to the development of superficial and
deep lower limb venous reflux, and thus VV and CVU,
through the increased occurrence of clinical and subclinical
thrombosis. An alternative hypothesis is that the presence
of VV and CVU leads to the development of an acquired
thrombophilic state. Although the inflammation associated
with CVU may lead to an increase in the level of certain
coagulation factors and other moieties involved in coagu-
lation, it does not explain the observed excess numbers of
inherited thrombophilias, or the high levels of HHcy. Nor
does it explain the previous observation that the relation-ship between thrombophilia and CVU is as strong in healed
as it is in open ulcers,3 or the present observation that of all
the thrombophilias, only factor VIII levels showed any
correlation with inflammation, as determined by CRP and
ESR levels.
The recognition of thrombophilia as an important risk
factor for the development of chronic venous insufficiency,
culminating in CVU, should open up new avenues for
prevention and intervention. In particular, this new under-
standing should lead to the evaluation of the ability of
warfarin and other newer and novel anticoagulants to pre-
vent and treat the complications of lower limb venous
disease. Several case reports and small case series have found
beneficial effects of warfarin,38,39 dalteparin,40 clopi-
dogrel,40 and aspirin26 on the healing of CVU associated
with thrombophilic defects. Further work is required to
delineate the relationship between thrombophilia and
chronic venous insufficiency.
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